We are contrasting Allakos Inc. (NASDAQ:ALLK) and Molecular Templates Inc. (NASDAQ:MTEM) on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allakos Inc. | 40 | 0.00 | N/A | -1.27 | 0.00 |
| Molecular Templates Inc. | 6 | 12.73 | N/A | -1.05 | 0.00 |
We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Allakos Inc. and Molecular Templates Inc.
Profitability
Table 2 provides the net margins, return on assets and return on equity of the two firms.
| Net Margins | Return on Equity | Return on Assets | |
| Allakos Inc. | 0.00% | -46.6% | -33.6% |
| Molecular Templates Inc. | 0.00% | -35.6% | -26.4% |
Liquidity
20.5 and 20.5 are the respective Current Ratio and a Quick Ratio of Allakos Inc. Its rival Molecular Templates Inc.’s Current and Quick Ratios are 3.2 and 3.2 respectively. Allakos Inc. has a better chance of clearing its pay short and long-term debts than Molecular Templates Inc.
Insider & Institutional Ownership
The shares of both Allakos Inc. and Molecular Templates Inc. are owned by institutional investors at 85% and 72.5% respectively. Comparatively, insiders own roughly 0.7% of Molecular Templates Inc.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Allakos Inc. | 2.97% | 10.77% | 19.79% | -21.67% | 0% | -20.32% |
| Molecular Templates Inc. | 5.22% | 23.35% | 63.33% | 66.88% | -13.45% | 89.6% |
For the past year Allakos Inc. had bearish trend while Molecular Templates Inc. had bullish trend.
Summary
Molecular Templates Inc. beats on 5 of the 7 factors Allakos Inc.
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
